Breaking News
Investing Pro 0
Donate to earthquake relief efforts in Turkey and Syria Donate

Amgen says experimental obesity drug has promising durability

Stock Markets Dec 03, 2022 06:36PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: An Amgen sign is seen at the company's office in South San Francisco, California October 21, 2013 REUTERS/Robert Galbraith
 
LLY
+0.60%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AMGN
+0.06%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
NVO
+1.10%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Deena Beasley

LOS ANGELES (Reuters) - Amgen Inc (NASDAQ:AMGN)'s experimental obesity drug demonstrated promising durability trends in an early trial, paving the way for a larger mid-stage study early next year, company officials said ahead of a data presentation on Saturday.

The small Phase I trial found that patients maintained their weight loss for 70 days after receiving the highest tested dose of the injected drug, currently known as AMG133.

Amgen shares have gained about 5% since the company said on Nov. 7 that 12 weeks of trial treatment at the highest monthly dose of AMG133 resulted in mean weight loss of 14.5%.

At 150 days after the last dose, maintained weight loss had dropped to 11.2% below original weight at the start of the trial, according to findings detailed at a meeting of World Congress of Insulin Resistance, Diabetes and Cardiovascular Disease in Los Angeles.

Patients treated with AMG133 did have side effects including nausea and vomiting, but most cases were mild and resolved within a couple of days after the first dose, Amgen said.

The U.S. Centers for Disease Control and Prevention estimates that more that 40% of the U.S. population is obese, costing nearly $173 billion annually. It is a primary cause of type 2 diabetes and been linked to heart disease, certain cancers and other health complications such as more severe COVID-19.

The weight loss field has gained renewed medical and investor attention in recent months after diabetes drugs from Eli Lilly (NYSE:LLY) and Co and Novo Nordisk (NYSE:NVO), known as semaglutide and tirzepatide, were proven to help obese patients lose weight.

Both of those drugs, which need to be injected every two weeks, are designed to activate GLP-1, a hormone that triggers the feeling of fullness in the body after eating.

Amgen's AMG133 also targets GLP-1, but has a dual mechanism which aims at the same time to block activity of a gene known as GIP.

The drug was developed from work at Amgen to identify genetic signals associated with lower fat mass and body weight, and also healthy metabolic profiles, explained Saptarsi Haldar, head of cardiovascular metabolic discovery at Amgen.

"Genetics clearly showed in multiple large populations that decreased activity genetically of the GIP receptor gene was associated with lower BMI (body mass index)," he said.

The California-based biotech said it plans to launch a larger mid-stage study of AMG133 early next year, which will enroll a broader range of patients, including those with additional health conditions such as diabetes.

JP Morgan analyst Chris Schott earlier this month said that if all goes well, a Phase III study of AMG133 could begin in 2024, with a launch expected in 2026 or 2027, if approved.

Amgen says experimental obesity drug has promising durability
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (1)
Marcus LL
Marcus LL Dec 03, 2022 11:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
So now there's a drug that replaced self control?
Jimmy Doodoo
JimmyD Dec 03, 2022 11:15PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
It's hard to expect self control when these people don't ever feel full.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email